Braftovi ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

braftovi

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - Æxlishemjandi lyf - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.

Vantobra (previously Tobramycin PARI) ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

vantobra (previously tobramycin pari)

pari pharma gmbh - tóbramýcíni - respiratory tract infections; cystic fibrosis - sýklalyf fyrir almenn nota, - vantobra er ætlað fyrir stjórnun langvarandi lungum sýkingu vegna pseudomonas tilhneiging til að hætta í sjúklinga á aldrinum 6 ára og eldri fengið lungnasjúkdóm (samanber). Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Zeposia ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

zeposia

bristol-myers squibb pharma eeig - ozanimod stutt og long-term - multiple sclerosis, relapsing-remitting; colitis, ulcerative - Ónæmisbælandi lyf - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Spiolto Respimat Innöndunarlausn 2,5/2,5 míkróg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

spiolto respimat innöndunarlausn 2,5/2,5 míkróg

boehringer ingelheim international gmbh* - tiotropii bromidum inn; olodaterolum hýdróklóríð - innöndunarlausn - 2,5/2,5 míkróg